(19)
(11) EP 4 824 250 A2

(12)

(88) Date of publication A3:
14.08.2025

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24829095.9

(22) Date of filing: 13.12.2024
(51) International Patent Classification (IPC): 
C12N 15/113(2010.01)
A61K 31/713(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 2310/321; C12N 2310/322; C12N 15/113; C12N 2310/14; C12N 2310/315; C12N 2310/351; C12N 2310/346; C12N 2310/317
 
C-Sets:
  1. C12N 2310/321, C12N 2310/3521;
  2. C12N 2310/322, C12N 2310/3533;

(86) International application number:
PCT/EP2024/086234
(87) International publication number:
WO 2025/125576 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 15.12.2023 EP 23217288
06.02.2024 WO PCT/EP2024/052934

(71) Applicant: Tangram Therapeutics PLC
London W2 6BD (GB)

(72) Inventors:
  • PURSELL, Natalie
    London W26BD (GB)
  • VICTOR WHITMORE, Alan
    London W26BD (GB)
  • MALANDRAKI-MILLER, Sophia
    London W26BD (GB)
  • DE SANTIAGO, Ines
    London W26BD (GB)
  • SAGINC GIANNOUSTAS, Gaye
    London W26BD (GB)

(74) Representative: CMS Cameron McKenna Nabarro Olswang LLP 
Cannon Place 78 Cannon Street
London EC4N 6AF
London EC4N 6AF (GB)

   


(54) INHIBITORS OF EXPRESSION AND/OR FUNCTION